1HAGENBUCH B,MEIER P J.The superfamily of organic anion transporting polypeptides[J].Biochim Biophys Acta,2003,1609 (1):1-18.
2KOBAYASHI D,NOZAWA T,IMAI K,et al.Involvement of human organic anion transporting polypeptide OATP-B (SLC21 A9) in pH-dependent transport across intestinal apical membrane[J].J Pharmacol Exp Ther,2003,306(2):703-708.
3CVETKOVIC M,LEAKE B,FROMM M F,et al.OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine[J].Drug Metab Dispos,1999,27(8):866-871.
4PERLOFF M D,VON MOLTKE L L,GREENBLATT D J.Fexofenadine transport in Caco-2 cells:inhibition with verapamil and ritonavir[J].J Clin Pharmacol,2002,42 (11):1269.
5Allegra(fexofenadine) Prescribing Information.Physician' s Desk Reference[M].Montvale(NJ):Medical Economics,2000,1343-1344.
6MEREDITH D,BOYD C A.Structure and function of eukaryotic peptide transporters[J].Cell Mol Life Sci,2000,57 (5):754-778.
9BERGAN T.Pharmacokinetic properties of the cephalosporins[J].Drugs,1987,34(Suppl 2):89-104.
10HU M,SUBRAMANIAN P,MOSBERG H I,et al.Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa:carrier kinetics,intestinal permeabilities,and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa[J].Pharm Res,1989,6(1):66-70.
二级参考文献82
1[1]Bush JA, Li G. Cancer chemoresistance: the relationship between P53 and Multidrug resistance [ J]. Int J Cancer,2002,98 ( 3 ) :323-330.
2[2]Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette ( ABC ) transporter superfamily [J]. Genome Res,2001,11(7) :1156-1166.
3[3]Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrugresistance gene in human tumors and tissues [ J ]. Proc Natl Acad Sci USA,1987,84( 1 ) :265-269.
4[4]Chin JE, Chen C J, Kriegler M,et al. Structure and expression of the human MDR (P-glycoprotein) gene family [ J ]. Mol Cell Biol, 1989,9(9) :3808-3820.
6[6]Schinkel AH, Wagenaar E , Mol CA, et al. P-glycoprotein in the blood brain barrier of mice influences the brain penetration and pharmacological activity of many drugs [ J]. J Clin Invest, 1996,97(11): 2517-2524.
7[7]Xie R, Hammarlund-Udenaes M, de Boer AG, et al. The role of P-glycoprotein in blood brain barrier transport of morphine:transcortical microdialysisstudies in Mdr1a ( / ) and Mdr1a (+/+) mice [J]. Br J Pharrnacol.1999,128(3) :563-568.
8[8]Rao VV, Dahlhejmer JL, Bardgett EM, et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the bloodcerebrospinal-fluid drug-permeability barrier [ J ]. Proc Natl Acad Sci USA ,1999,96(7) :3900-3905.
9[9]Gottesman MM, Tito F, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transportes [ J ]. Nature Cancer Rev,2002,2( 1 ) :49-58.
10[10]Paulusma CC,Piter J B, Guido JR,et al. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene [J]. Science,1996,271(5252): 1126-1128.
7Korjamo T, Honkakoski P, Toppinen M R, et al. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines [J]. Eur Pharm Sci, 2005, 26(3-4):266-279.
8Terry R S, Olafur G. Progress in understanding the structureactivity relationships of P-glycoprotein [J]. Adv Drug Deliv Rev, 2002, 54(3):315-328.
9Comair G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo [J ]. Int J Pharm, 2004, 278(1): 119-131.
